Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.

ABSTRACT:

SUBMITTER: Alistar A 

PROVIDER: S-EPMC5635818 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature